Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Standard
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. / Grabinski, Nicole; Ewald, Florian; Hofmann, Bianca T.; Staufer, Katharina; Schumacher, Udo; Nashan, Björn; Jücker, Manfred.
In: MOL CANCER, Vol. 11, 2012, p. 85.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
AU - Grabinski, Nicole
AU - Ewald, Florian
AU - Hofmann, Bianca T.
AU - Staufer, Katharina
AU - Schumacher, Udo
AU - Nashan, Björn
AU - Jücker, Manfred
PY - 2012
Y1 - 2012
N2 - Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moderate antitumor efficacy which may be due to the feedback activation of AKT after mTOR inhibition. In this study, we analyzed the effects of dual inhibition of mTOR and AKT on the proliferation of HCC cell lines. In addition, we measured the feedback activation of each of the AKT isoforms after mTOR inhibition in HCC cell lines and their enzymatic activity in primary samples from HCC patients.
AB - Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moderate antitumor efficacy which may be due to the feedback activation of AKT after mTOR inhibition. In this study, we analyzed the effects of dual inhibition of mTOR and AKT on the proliferation of HCC cell lines. In addition, we measured the feedback activation of each of the AKT isoforms after mTOR inhibition in HCC cell lines and their enzymatic activity in primary samples from HCC patients.
U2 - 10.1186/1476-4598-11-85
DO - 10.1186/1476-4598-11-85
M3 - SCORING: Journal article
VL - 11
SP - 85
JO - MOL CANCER
JF - MOL CANCER
SN - 1476-4598
ER -